SIRT1 and metabolic dysfunction-associated steatohepatitis: Compared with non-NASH patients (the N0 subgroup), definite NASH patients (N2) in the HC group showed higher expression of SREBF2 and lower expression of SIRT1; overall, NASH patients (N1 and N2 subgroups) in the LC group showed higher expression of mTOR.